Atención al cliente
BD manufactures and sources products from multiple locations around the world
BD has contingency plans if a product or raw material is deemed at risk
BD is deploying our capabilities, expertise and scale to address critical health needs related to coronavirus
Updated April 17, 2020
BD is closely monitoring the COVID-19 (coronavirus) situation across the world and guidance from the U.S. Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO) and health officials in a variety of affected countries to protect the health and safety of BD employees while ensuring continued availability of BD’s critical medical devices at this unprecedented time.
BD manufactures and sources product from multiple locations around the world. Each of our manufacturing and distribution centers that provide medical devices essential to diagnosing or treating patients with coronavirus are operational, with 95 percent of our critical-to-COVID locations operating at or close to full capacity. We have also enacted business continuity plans to minimize the risk of disruption to our customers.
In Greater Asia, the vast majority of BD’s manufacturing and distribution centers are operating normally. In Japan, we do not expect any disruptions in our manufacturing or ability to serve customers as a result for the State of Emergency declaration in seven prefectures. We have implemented business continuity measures in response to the “lockdown” directive in Singapore and Malaysia, which has temporarily restricted the number of employees able to report to work in these countries. As a result, these plants are currently operating at a reduced capacity through May 4 while we work with local government agencies to seek an exemption and assess additional business continuity options to maximize our manufacturing output. We are working with suppliers and our manufacturing sites to maintain sufficient inventory of the products manufactured at these sites, and no material product impact is projected at this time.
In India, our manufacturing site in Haryana is operating normally with minimal disruptions. We are continuing to work closely with third-party logistics providers, distributors, and the local and national government in India on transportation challenges as a result of the extended lockdown through May 3. At this time, we do not expect there to be any impact to product supply.
In addition, BD continues to work closely with our key suppliers around the world that provide raw materials and components to BD manufacturing plants. We have implemented business continuity measures to mitigate the risk of potential supplier disruption, including partnering with local governments to seek “essential business” exemptions for key suppliers where necessary. For products considered critical-to-COVID, BD continues to have sufficient raw material and component inventory to meet manufacturing demand.
BD is making every effort to ensure product is transported to distributors and customers as quickly and efficiently as possible. We are actively monitoring our global logistics and transportation network, taking necessary actions to work around global capacity and border constraints to minimize the risk of any customer delays.
In response to very high demand for our critical medical devices, we have ramped up production, and we are closely monitoring inventory and customer ordering to ensure supply continuity. While we continue to meet current demand for the vast majority of our products, we are seeing high demand in select product categories because of a prolonged flu season and the coronavirus pandemic.
As a result, the following products are on manual inventory allocation to supply our customers as much as possible:
Manual inventory allocation is an internal process that allows BD to retain greater visibility and control of available product to effectively serve our customers by ensuring an equitable allocation of available inventory. This includes reviewing orders for disproportionate quantities based on historic demand. For U.S. customers, an up-to-date list of products on manual inventory allocation can be found at bd.com/allocation.
While this may result in longer than normal call times for customer service, customers do not need to take any special action related to this process and it will not otherwise delay the ordering or shipping process. Customers may receive a backorder notification when an order is placed, and orders may be filled as partial shipments as inventory becomes available. We believe these practices will help minimize supply disruptions by ensuring an equitable allocation of available inventory.
BD has business continuity plans for these types of situations. If a product or raw material is deemed at risk, BD will adopt numerous contingency plans including seeking alternative suppliers, expediting shipments, redeploying raw materials and/or finished goods from other parts of the BD network and placing at-risk products on order review to prevent hoarding behavior. BD also institutes preventative pandemic precautions at facilities to protect employees, including increasing cleaning protocols, implementing temperature screenings for on-site employees, encouraging work-from-home for all employees who are able, suspending travel and group meetings, limiting on-site visitors, and regularly educating employees about good hygiene and health practices, including social distancing, self-quarantining and handwashing.
As one of the largest global medical technology companies in the world, BD is deploying our capabilities, expertise and scale to address critical health needs related to coronavirus – from our diagnostic offerings to identify COVID-19, to real-time informatics and electronic surveillance technology, to essential medical devices to support patient care. Specifically, BD:
In addition, BD is deploying $1.1 million in cash and product donations to seven non-profit organizations – Direct Relief, the International Medical Corps, Americares, the World Health Organization-United Nations Foundation COVID-19 Solidarity Response Fund, Project HOPE, the CDC Foundation and the Wuhan Red Cross – to advance their work to contain COVID-19, support healthcare workers and treat patients in countries throughout the world.
Tenga en cuenta que es posible que no todos los productos, servicios o funciones estén disponibles en su región. Consulte al representante local de BD.
BD Iberia le informa de que el contenido de esta página está destinado exclusivamente a profesionales sanitarios. Si Ud. es un profesional por favor pulse "SI" para continuar y si no lo es, pulse "NO" para salir. Gracias.